Skip to main content
SpringerLink
Log in
Book cover

Combination Therapy of AIDS pp 25–40Cite as

Birkhäuser

A perspective of the history of HAART

  • Chapter

  • 135 Accesses

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

The history of HIV treatment is characterised by a rapid development. In 1987, 6 years after the discovery of AIDS, the US Food and Drug administration approved the first drug against HIV. Since then three different classes of antiretroviral drugs including 16 drugs are currently available, others have reached phase III studies and immunotherapy and vaccines are in development.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.N Engl J Med 317: 185–191

    Article  PubMed  CAS  Google Scholar 

  2. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS et al. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.N Engl J Med 317: 192–197

    Article  PubMed  CAS  Google Scholar 

  3. Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E et al. (1990) A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.N Engl J Med 323: 1009–1014

    Article  PubMed  CAS  Google Scholar 

  4. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD et al. (1990) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.Ann Intern Med 112: 727–737

    Article  PubMed  CAS  Google Scholar 

  5. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS et al. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.N Engl J Med 322: 941–949

    Article  PubMed  CAS  Google Scholar 

  6. Concorde Coordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection.Lancet 343: 871–881

    Article  Google Scholar 

  7. Larder BA, Kellam P, Kemp SD (1991) Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.AIDS 5: 137–144

    Article  PubMed  CAS  Google Scholar 

  8. Fitzgibbon JE, Howell RM, Schwartzer TA, Gocke DJ, Dubin DT (1991) Invivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy.AIDS Res Hum Retroviruses 7: 265–269

    Article  PubMed  CAS  Google Scholar 

  9. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G et al. (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.N Engl J Med 327: 581–587

    Article  PubMed  CAS  Google Scholar 

  10. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA 3rd, Gupta P, Rasheed S, Coombs R et al. (1994) Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.J Infect Dis 169: 722–729

    Article  PubMed  CAS  Google Scholar 

  11. Moyle G (2000) Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?Drug Saf 23: 467–481

    Article  PubMed  CAS  Google Scholar 

  12. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG et al. (1993) Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.Ann Intern Med 119: 786–793

    Article  PubMed  CAS  Google Scholar 

  13. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG (1995) Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The MAID AIDS Clinical Trials Group.Ann Intern Med 122: 24–32

    Article  PubMed  CAS  Google Scholar 

  14. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M et al. (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.N Engl J Med 335: 1081–1090

    Article  PubMed  CAS  Google Scholar 

  15. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A et al. (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.N Engl J Med 335: 1091–1098

    Article  PubMed  CAS  Google Scholar 

  16. Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D’Aquila RT et al. (1998) Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200–500 CD4 cells/n[11113(ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.J Infect Dis 177: 617–624

    Article  PubMed  CAS  Google Scholar 

  17. Delta Coordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in infected individuals. individuals.Lancet 348: 283–291

    Article  Google Scholar 

  18. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.N Engl J Med 333: 1662–1669

    Article  PubMed  CAS  Google Scholar 

  19. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H (1996) Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naïve patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.JAMA 276: 118–125

    Article  PubMed  CAS  Google Scholar 

  20. Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhoj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L et al. (1996) Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.JAMA 276: 111–117

    Article  PubMed  CAS  Google Scholar 

  21. Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T et al. (1999) The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.J Infect Dis 180: 351–358

    Article  PubMed  CAS  Google Scholar 

  22. Kuritzkes DR, Marchner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME et al. (1999) Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.AIDS 13: 685–694

    Article  PubMed  CAS  Google Scholar 

  23. Danner SA, Can A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V et al. (1995) A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.N Engl J Med 333: 1528–1533

    Article  CAS  Google Scholar 

  24. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM et al. (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.N Engl J Med 333: 1534–1539

    PubMed  CAS  Google Scholar 

  25. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, Weber JN (1995) Safety and activity of saquinavir in HIV infection.Lancet 345: 952–955

    Article  PubMed  CAS  Google Scholar 

  26. Steigbigel R, Berry P, Teppler H et al. (1996) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.I1 th International Conference on AIDS 7–12 July 1996, Vancouver, BC, Canada, Abstract Mo.B.412

    Google Scholar 

  27. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyayskiy T, Niu P, Lyons N et al. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.Nat Med 2: 760–766

    Article  PubMed  CAS  Google Scholar 

  28. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ et al. (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.N Engl J Med; 334: 1011–1017

    Article  PubMed  CAS  Google Scholar 

  29. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.N Engl J Med 337: 734–739

    Article  PubMed  CAS  Google Scholar 

  30. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.Ann Intern Med 126: 946–954

    Article  PubMed  CAS  Google Scholar 

  31. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med 338: 853–860

    Article  PubMed  Google Scholar 

  32. Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R et al. (1997) Reductions in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.Antiviral Ther 2: 175–183

    CAS  Google Scholar 

  33. Can A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA (2000) A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombol study.AIDS 14: 1171–1180

    Article  Google Scholar 

  34. Clendeninn N, Quart B, Anderson R, Knowles M, ChangY (1988) Analysis of long-term virologic data from the Viracept®(Nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays.5th Conference on Retroviruses and Opportunistic Infections 1–5 February 1998, Chicago, Illinois, USA, Abstract 372

    Google Scholar 

  35. Bart PA, Gizzard GP, Gallant S, Welbon C, Graziosi C, Chave JP, Meylan P, Martin G, Steel H, Spreen W et al. (1998) Combination abacavir/amprenavir therapy in HIV-1-infected antiretroviral-naïve subjects with CD4+ counts >400 cells/RI and viral load >5,000 copies/ml.5th Conference on Retroviruses and Opportunistic Infections 1–5 February 1998, Chicago, Illinois, USA, Abstract 365

    Google Scholar 

  36. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.Lancet 353: 863–868

    Article  PubMed  CAS  Google Scholar 

  37. Lucas GM, Chaisson RE, Moore RD (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.Ann Intern Med 131: 81–87

    Article  PubMed  CAS  Google Scholar 

  38. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S (2003) Results of a phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects.J Acquir Immune Defic Syndr 32: 18–29

    Article  PubMed  CAS  Google Scholar 

  39. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S et al. (1999) Ritonavir and saquinavir combination therapy for the treatment of HIV infection.AIDS 13: 213–224

    Article  PubMed  CAS  Google Scholar 

  40. Voigt E, Wickesberg A, Wasmuth JC, Gute P, Locher L, Salzberger B, Wohnmann A, Adam A, Weitner L, Rockstroh JK (2002) First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results.HIV Med 3: 277–282

    Article  PubMed  CAS  Google Scholar 

  41. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D et al. (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients.JAMA 279: 930–937

    Article  PubMed  CAS  Google Scholar 

  42. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D et al. (2000) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med; 341: 1865–1873

    Article  Google Scholar 

  43. van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, Wood R, Squires K, Katlama C, Santos B et al. (2003) Results of the 2NN study: a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine.10th Conference on Retroviruses and Opportunistic Infections 10–14 February 2003, Boston, Massachusetts, USA, Oral Abstract 176

    Google Scholar 

  44. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J (2000) Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.AIDS 14: 807–812

    Article  PubMed  CAS  Google Scholar 

  45. Rachlis A, Becker S, Gill J, Dejesus E, Pierone G, Ruiz N, Aznar E (2001) Successful substitution of protease inhibitors with efavirenz in patients with undetectable viral loads.1st International AIDS Society Conference on HIV Pathogenesis and Treatment 8–11 July 2001, Buenos Aires, Argentina, Abstract 418

    Google Scholar 

  46. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, Casamitjana R, Mallolas J, Gatell JM (2000) Impact of switching from human immunodeficiency virus type 1 protease inhibitor to efavirenz in successfully treated adults with lipodystrophy.Clin Infect Dis 31: 1266–1273

    Article  PubMed  CAS  Google Scholar 

  47. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S et al. (2001) Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.J Acquir Immune Def Syndr 27: 229–236

    CAS  Google Scholar 

  48. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R et al. (2001) Simplification with abacavir-based triple nucleoside therapyversus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.AIDS 15: 1517–1526

    Article  PubMed  CAS  Google Scholar 

  49. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E et al. (2002) A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.J Infect Dis 185: 1251–1260

    Article  PubMed  CAS  Google Scholar 

  50. Can A, Hudson J, Chuan J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.AIDS 15: 1811–1822

    Article  Google Scholar 

  51. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M et al. (2001) Abacavir-lamuvidine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral naïve HIV-infected adults: a randomized equivalence trial.JAMA 285: 1155–1163

    Article  PubMed  CAS  Google Scholar 

  52. Martinez E, Mocroft A, Garcia-Viejo M, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A et al. (2001) Risk of lipodystrophy in HIV-1 infected patients treated with protease-inhibitors: a prospective cohort study.Lancet 357: 592–598

    Article  PubMed  CAS  Google Scholar 

  53. Carr A, Samaras K, Chisholm J Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance.Lancet 351: 1881–1883

    Article  PubMed  CAS  Google Scholar 

  54. Mallal SA, John M, Moore CB, James JR, McKinnon EJ (2000) Contribution of nucleoside ana-logue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.AIDS 14: 1309–1316

    Article  PubMed  CAS  Google Scholar 

  55. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA (2001) Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included in the treatment of HIV-1 infection.AIDS 15: 847–855

    Article  PubMed  Google Scholar 

  56. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV (2002) MMWR Recomm Rep May 17: 1–55.http://www.hivatis.org57 The EACS Euroguidelines Group (2003) European guidelines for the clinical management and treatment of HIV infected adults in Europe.AIDS supplement to volume 17, 02 June 2003

  57. Delta Coordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in infected individuals. individuals. Lancet 348: 283–291

    Article  Google Scholar 

  58. Ruiz L, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, MoralesLopetegi K, Autran B et al. (2001) HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15: F19¡ªF27

    Article  Google Scholar 

  59. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW et al. (2001) Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci US A 98: 15161–15166

    Article  PubMed  CAS  Google Scholar 

  60. Hirschel B, Fagard C, Oxenius A, Gunthard H, Garcia F. (2002) A prospective trial of treatment interruptions in HIV infection. 9th Conference on Retroviruses and Opportunistic Infections 24–28 February 2002, Seattle, Washington, USA, Abstract 528-M

    Google Scholar 

  61. Staszewski S, Gallant J, Pozniak A, Suleiman JMAH, Dejesus E, Koenig E, Coleman S, Lu B, Cheng AK, Coakley DF (2002) Efficacy and safety of tenofovir disoproxil fumarate versus stavudine when used in combination with lamivudine and efavirenz in HIV-1 infected naïve patients to antiretroviral treatment: 48 weeks interim results. XIV“ International AIDS Conference 7–12 July 2002, Barcelona, Spain, Abstract Or17

    Google Scholar 

  62. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Conninck E, Conway B et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385–394

    Article  PubMed  CAS  Google Scholar 

  63. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B (2002) Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16: 209–218

    Article  PubMed  Google Scholar 

  64. Katlama C, Dominguez S, Duvivier C, Delaugerre C, Peytavin G, Legrand M, Calvez V, Gourlain K, Costagliola D (2003) Long-term benefit of treatment interruption in salvage therapy (GIGHAART ARNS 097). 10th Conference on Retroviruses and Opportunistic Infections 10–14 February 2003, Boston, Massachusetts, USA, Oral Abstract 68

    Google Scholar 

  65. Lalezari JP, Henry K, O’Hearn M, Lefebvre E, Monaner J, Piliero P, Walmsley S, Chung J, Fang L, Delehanty J et al. (2002) Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone: Week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (AVR) resistance. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 27–30 September 2002, San Diego, California, USA, Abstract H-1074

    Google Scholar 

  66. Ho DD (1998) Toward HIV eradication or remission: the tasks ahead. Science 280: 1866–1867

    Article  PubMed  CAS  Google Scholar 

  67. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B (1998) Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351: 1682–1686

    Article  PubMed  CAS  Google Scholar 

  68. Kovacs JA, Vogel S, Albert TM, Falloon J, Davey RT Jr, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M et al. (1996) Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335: 1350–1356

    Article  PubMed  CAS  Google Scholar 

  69. Hengge UR, Goos M, Esser S, Exner V, Dotterer, Wiehler H, Borchard C, Muller K, Beckmann A, Eppner MT et al. (1998) Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 12: F225¡ªF234

    Article  Google Scholar 

  70. Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, Saracco M, Nelson E et al. (2000) A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >_350 cells/mm3. J Infect Dis 181: 1614–1621

    Article  PubMed  CAS  Google Scholar 

  71. Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG,Dewar RL, Sahner DK et al. (2000) Immunologic and virologie effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284: 183–189

    Article  PubMed  CAS  Google Scholar 

  72. Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, Sampson J, Verheggen R, Zeh D, Markowitz NP (2002) Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of >_300 cells/mm3. J Acquir Immune Defic Syndr 29: 221–231

    PubMed  CAS  Google Scholar 

  73. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA et al. (2003) Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 17: 343–351

    Article  PubMed  CAS  Google Scholar 

  74. Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D (2002) Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS 16: 2027–2034

    Article  PubMed  CAS  Google Scholar 

  75. Frumkin L (1997) Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection. Curr Opin Hematol 4: 200–206

    Article  PubMed  CAS  Google Scholar 

  76. Hardy GA, Imami N, Gotch FM (2002) Improving HIV-specific immune responses in HIV-infected patients. J HIV Ther 7: 40–45

    PubMed  CAS  Google Scholar 

  77. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O’Connor DH, Davis BT, Lee PK et al. (2002) HIV-1 superinfection despite broad CD8+ T -cell responses containing replication of the primary virus. Nature 420: 434–439

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Saint-Pierre University Hospital, 322 rue Haute, Brussels, 1000, Belgium

    Deborah Konopnicki & Nathan Clumeck

Authors
  1. Deborah Konopnicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathan Clumeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Rega Institute, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000, Leuven, Belgium

    Erik D. A. De Clercq  & Anne-Mieke I. Vandamme  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Basel AG

About this chapter

Cite this chapter

Konopnicki, D., Clumeck, N. (2004). A perspective of the history of HAART. In: De Clercq, E.D.A., Vandamme, AM.I. (eds) Combination Therapy of AIDS. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7869-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7869-2_2

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9604-7

  • Online ISBN: 978-3-0348-7869-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation